4.4 Review

Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Pharmacology & Pharmacy

Current and emerging drug treatment strategies for polycystic ovary syndrome

Nafiye Helvaci et al.

Summary: This article provides an overview of pharmacotherapies for the management of women with polycystic ovary syndrome (PCOS) who do not seek pregnancy. It emphasizes the need for individualized treatment and targeting specific symptoms. However, the complexity and heterogeneity of PCOS pose challenges in finding safer and more effective therapeutic strategies.

EXPERT OPINION ON PHARMACOTHERAPY (2023)

Review Reproductive Biology

Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment

Han Zhao et al.

Summary: Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by chronic ovulation dysfunction and overabundance of androgens; it affects 6-20% of women of reproductive age. PCOS involves various pathophysiological factors, and women with PCOS usually have significant insulin resistance (IR), which is a major cause of PCOS. IR and compensatory hyperinsulinaemia have different causes in different tissues, and IR varies among different PCOS phenotypes. Genetic and epigenetic changes, hyperandrogenaemia, and obesity worsen IR. Insulin sensitization drugs are a new treatment modality for PCOS.

JOURNAL OF OVARIAN RESEARCH (2023)

Review Nutrition & Dietetics

Ketogenic Diet as Medical Prescription in Women with Polycystic Ovary Syndrome (PCOS)

Luigi Barrea et al.

Summary: This review aims to assess the scientific evidence supporting very low-calorie ketogenic diet (VLCKD) as an effective measure for treating polycystic ovary syndrome (PCOS) and its associated metabolic disorders. Preliminary data suggest significant improvements in weight, metabolic profile, and insulin resistance following VLCKD. However, more research is needed to substantiate these findings.

CURRENT NUTRITION REPORTS (2023)

Review Biochemistry & Molecular Biology

Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance

Rok Herman et al.

Summary: Polycystic ovary syndrome (PCOS) is a common disorder in women of reproductive age, characterized by hyperandrogenemia, reproductive changes, polycystic ovary morphology, and insulin resistance (IR). The primary pathophysiological process in its etiology has not yet been identified, but it is believed to involve insulin metabolism disruption and hyperandrogenemia. This review focuses on the role of insulin secretion, clearance, and decreased sensitivity in target cells as potential primary insults in PCOS pathogenesis, as well as the molecular mechanism behind IR in PCOS.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Obstetrics & Gynecology

Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment

Chuan Xing et al.

Summary: PCOS is a common endocrine disease in women, characterized by HA, chronic anovulation, and PCOM. SHBG plays a key role in regulating hyperandrogenism and metabolic abnormalities in PCOS patients.

INTERNATIONAL JOURNAL OF WOMENS HEALTH (2022)

Article Obstetrics & Gynecology

Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study

Karen E. Elkind-Hirsch et al.

Summary: This study aimed to evaluate the efficacy and safety of the GLP-1 analog liraglutide 3 mg (LIRA 3 mg) in reducing body weight and hyperandrogenism in women with obesity and polycystic ovary syndrome (PCOS). The results showed that LIRA 3 mg was superior to placebo in reducing body weight, lowering androgen levels, and improving cardiometabolic parameters.

FERTILITY AND STERILITY (2022)

Review Medicine, Research & Experimental

GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons

Georgios S. Papaetis et al.

Summary: PCOS is a disorder involving multiple organ systems and cells, influenced by environmental and epigenetic factors. GLP-1R agonists have shown significant effects in weight loss and improving insulin resistance, potentially beneficial for PCOS patients.

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2022)

Article Endocrinology & Metabolism

The Degree of Menstrual Disturbance Is Associated With the Severity of Insulin Resistance in PCOS

Xiaojia Li et al.

Summary: This study investigated the association between menstrual disturbance and insulin resistance in women with PCOS, finding a positive correlation between the degree of disturbance and IR severity, indicating that the intervals of vaginal bleeding may serve as a predictive measure for the severity of IR in PCOS.

FRONTIERS IN ENDOCRINOLOGY (2022)

Review Public, Environmental & Occupational Health

The relationship between polycystic ovary syndrome and insulin resistance from 1983 to 2022: A bibliometric analysis

Tong Chen et al.

Summary: Through bibliometric analysis, this study reveals the research hotspots and trends in the field of PCOS and IR, providing reference for future research.

FRONTIERS IN PUBLIC HEALTH (2022)

Review Biochemistry & Molecular Biology

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

Mojca Jensterle et al.

Summary: Despite lifestyle intervention and symptomatic management being the main treatments for PCOS, GLP-1 receptor agonists have shown superior weight loss effects and additional metabolic, reproductive, and cardiovascular benefits compared to other treatments. However, concerns about contraception and washout periods before pregnancy have limited their acceptance in the clinical community treating PCOS.

BIOMEDICINES (2022)

Editorial Material Cardiac & Cardiovascular Systems

Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists

Kosuke Sawami et al.

Summary: Obesity is associated with metabolic disturbances and increased risk of obesity-related cardiovascular diseases. Current anti-obesity drugs have shown weight loss effects but have not demonstrated significant reduction in the risk of cardiovascular diseases. Recent research suggests glucagon-like peptide-1 receptor agonists as potential first-line anti-obesity agents for preventing obesity-related cardiovascular diseases.

CARDIOVASCULAR DIABETOLOGY (2022)

Review Pharmacology & Pharmacy

The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis

Shuo Yang et al.

Summary: This study compared the effects of oral antidiabetic drugs on reproductive hormones, metabolic and anthropometric markers, and menstrual frequency in patients with PCOS using network meta-analysis. GLP-1 receptor agonists combined with metformin appear to be preferable for improving hyperandrogenaemia, while metformin combined with TZDs may be associated with a beneficial effect on menstrual recovery.
Review Pharmacology & Pharmacy

Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities

Shiying Shao et al.

Summary: GLP-1 and GLP-1RAs play important roles in the treatment of diabetes and obesity by controlling glucose levels and promoting weight loss. They also have positive effects on autoimmune diseases, cardiovascular diseases, diabetic kidney disease, diabetic foot ulcers, polycystic ovary syndrome, and Alzheimer's disease.

PHARMACOLOGY & THERAPEUTICS (2022)

Review Cardiac & Cardiovascular Systems

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations

Dan Xu et al.

Summary: GLP-1 receptor agonists have been shown to significantly reduce the incidence of major cardiovascular events in patients with type 2 diabetes, but more research is needed to understand their cardiovascular protective effects in non-diabetic individuals.

CARDIOVASCULAR THERAPEUTICS (2022)

Review Endocrinology & Metabolism

Therapy of obesity in women with PCOS using GLP-1-benefits and limitations

Agnieszka Baranowska-Bik

Summary: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder in women of reproductive age. Obesity is common in PCOS patients and exacerbates insulin resistance, hyperinsulinemia, and hyperandrogenemia. Maintaining normal weight or treating overweight/obesity is crucial for these patients. Evidence supports the use of glucagon-like peptide 1 (GLP-1) analogues in the treatment of overweight/obese PCOS patients, leading to weight reduction, improved insulin resistance, decreased hyperandrogenemia, and potentially increased pregnancy rates.

ENDOKRYNOLOGIA POLSKA (2022)

Article Endocrinology & Metabolism

Glucagon-like peptide-1 control of GnRH secretion in female sheep

Leila Arbabi et al.

Summary: The study showed that GLP-1 may stimulate GnRH secretion at the level of the secretory terminals of GnRH neurons in the median eminence. It was found that the GLP-1 receptor is mainly expressed in Kisspeptin cells, with minimal expression in GnRH and NPY cells.

JOURNAL OF ENDOCRINOLOGY (2021)

Review Medicine, General & Internal

A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review

Mariana Cornelia Tilinca et al.

Summary: Obesity and type 2 diabetes mellitus have become a significant public health problem. Liraglutide, a GLP-1 RA, is effective in managing these metabolic disorders by improving glycemic control and reducing weight. Its safety and efficacy have been highlighted in clinical practice for patients with and without diabetes.

MEDICINA-LITHUANIA (2021)

Review Pharmacology & Pharmacy

Clinical Impact of Liraglutide as a Treatment of Obesity

Heshma Alruwaili et al.

Summary: Obesity is a chronic, complex disease that can lead to various complications. Achieving sustainable weight loss of more than 10% is crucial in improving or even reversing obesity-related complications. Liraglutide, a GLP-1 analogue, has shown significant weight reduction and maintenance benefits, as well as promoting cardiovascular disease risk reduction.

CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2021)

Review Pharmacology & Pharmacy

Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome

Georgios S. Papaetis et al.

CLINICAL DRUG INVESTIGATION (2020)

Review Endocrinology & Metabolism

From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management

Arianna Pani et al.

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2020)

Article Biochemistry & Molecular Biology

Incretins modulate progesterone biosynthesis by regulating bone morphogenetic protein activity in rat granulosa cells

Yuki Nishiyama et al.

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2018)

Review Endocrinology & Metabolism

Glucagon-like peptide 1 in health and disease

Andreas Andersen et al.

NATURE REVIEWS ENDOCRINOLOGY (2018)

Article Obstetrics & Gynecology

Polycystic Ovary Syndrome

Ricardo Azziz

OBSTETRICS AND GYNECOLOGY (2018)

Article Endocrinology & Metabolism

Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS

Signe Frossing et al.

ENDOCRINE CONNECTIONS (2018)

Article Endocrinology & Metabolism

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial

Signe Frossing et al.

DIABETES OBESITY & METABOLISM (2018)

Article Obstetrics & Gynecology

Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial

Malin Nylander et al.

REPRODUCTIVE BIOMEDICINE ONLINE (2017)

Article Endocrinology & Metabolism

Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential

Malin Nylander et al.

ENDOCRINE CONNECTIONS (2017)

Article Cell Biology

Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells

Wenjing He et al.

MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)

Article Medicine, General & Internal

Polycystic ovary syndrome

Ricardo Azziz et al.

NATURE REVIEWS DISEASE PRIMERS (2016)

Article Medicine, General & Internal

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial

Melanie J. Davies et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)

Article Medicine, General & Internal

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Xavier Pi-Sunyer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Endocrinology & Metabolism

Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats

Burcu Artunc-Ulkumen et al.

GYNECOLOGICAL ENDOCRINOLOGY (2015)

Article Endocrinology & Metabolism

Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome

Kadriye Aydin et al.

CLINICAL ENDOCRINOLOGY (2014)

Review Endocrinology & Metabolism

Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications

Evanthia Diamanti-Kandarakis et al.

ENDOCRINE REVIEWS (2012)

Article Endocrinology & Metabolism

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

A. Astrup et al.

INTERNATIONAL JOURNAL OF OBESITY (2012)

Article Endocrinology & Metabolism

Incretin levels in polycystic ovary syndrome

Jana Vrbikova et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)

Review Obstetrics & Gynecology

Follicle dynamics and anovulation in polycystic ovary syndrome

Stephen Franks et al.

HUMAN REPRODUCTION UPDATE (2008)

Article Radiology, Nuclear Medicine & Medical Imaging

GLP-1 receptor expression in human tumors and human normal tissues:: Potential for in vivo targeting

Meike Koerner et al.

JOURNAL OF NUCLEAR MEDICINE (2007)

Article Endocrinology & Metabolism

Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome

DA Ehrmann et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)

Article Endocrinology & Metabolism

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

T Apridonidze et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)